-
公开(公告)号：US20170327800A1
公开(公告)日：2017-11-16
申请号：US15663361
申请日：2017-07-28
CPC分类号： C12N9/12 , A61K38/00 , A61K38/179 , A61K38/45 , A61K45/06 , A61P7/06 , C12Y207/1103 , A61K2300/00
摘要： In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
-
公开(公告)号：US11827689B2
公开(公告)日：2023-11-28
申请号：US17245123
申请日：2021-04-30
发明人： Ravindra Kumar , Asya Grinberg , Dianne Sako , Robert Scott Pearsall , Roselyne Castonguay , Gang Li , Yossi Dagon , John Knopf
CPC分类号： C07K14/71 , A61K38/45 , C12N9/12 , C12Y207/1103 , A61K38/00 , C07K2319/30
摘要： In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK7 receptor and an extracellular domain of ActRIIB In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof.
-
公开(公告)号：US20230226146A1
公开(公告)日：2023-07-20
申请号：US18011261
申请日：2021-06-22
发明人： Janethe de Oliveira Pena , Peter Linde , Sachindra Joshi , Gang Li , Patrick Andre , Ravindra Kumar
CPC分类号： A61K38/1709 , A61K45/06 , A61P9/12
摘要： In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of pulmonary arterial hypertension, particularly treating, preventing or reducing the progression rate and/or severity of one or more pulmonary arterial hypertension associated complications.
-
4.发明申请公开(公告)号：US20230134083A1
公开(公告)日：2023-05-04
申请号：US17911347
申请日：2021-03-11
发明人： Gang Li , Ravindra Kumar
摘要： In some aspects, the disclosure relates to single-arm AetRIIA heteromultimers and sing-arm ActRIIB heteromultimers and methods of using such heteromultimers to treat, prevent, or reduce tire progression rate and/or severity of renal diseases or conditions, particularly treating, preventing or reducing the progression rate and/or severity of one or more renal-associated complications. The disclosure also provides methods of using a single-arm ActRIIA heteromultimer or single-arm ActRIIB heteromultimer to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, Alport syndrome, focal segmental glomerulosclerosis (FSGS), polycystic kidney disease, and/or chronic kidney disease.
-
公开(公告)号：US20220332778A1
公开(公告)日：2022-10-20
申请号：US17535100
申请日：2021-11-24
IPC分类号： C07K14/495 , A61K31/519 , A61K45/06 , C07K14/71
摘要： In part, the present disclosure relates methods for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or one or more complications of a myeloproliferative disorder. The present disclosure further relates methods for treating, preventing, or reducing the severity of a Janus kinase-associated disorder or one or more complications of a Janus kinase-associated disorder. In certain aspects the disclosure provides TβRII antagonists for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or a Janus kinase-associated disorder or one or more complications of a myeloproliferative disorder or a Janus kinase-associated disorder.
-
公开(公告)号：US20220306724A1
公开(公告)日：2022-09-29
申请号：US17687934
申请日：2022-03-07
发明人： Ravindra Kumar , Asya Grinberg , Erik M. Vogan
摘要： In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of red blood cells or a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.
-
公开(公告)号：US20220211806A1
公开(公告)日：2022-07-07
申请号：US17410175
申请日：2021-08-24
发明人： John Knopf , Jasbir Seehra
IPC分类号： A61K38/17 , C07K14/575 , C07K14/71
摘要： In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
-
公开(公告)号：US20220127330A1
公开(公告)日：2022-04-28
申请号：US17342015
申请日：2021-06-08
发明人： Jasbir Seehra
摘要： In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density and strength. In certain embodiments, the present invention provides ALK3 polypeptides, including ALK3-Fc fusion proteins.
-
公开(公告)号：US20220089683A1
公开(公告)日：2022-03-24
申请号：US17252525
申请日：2019-06-14
摘要： Disclosed herein are bi- and tri-functional fusion proteins comprising two or more of an activin antagonist domain, a TOPβ antagonist domain, and an immune checkpoint antagonist domain. In addition, the disclosure provides methods of treating cancer, a tumor, a pre-neoplastic disorder, a hyperproliferative disorder, or a dysplastic disorder comprising administering a bi- or tri-functional fusion protein comprising two or more of an activin antagonist domain, a TOPβ antagonist domain, and an immune checkpoint antagonist domain. Optionally, such methods further comprise administering an additional active agent or supportive therapy for treating the cancer, a tumor, a pre-neoplastic disorder, a hyperproliferative disorder, or a dysplastic disorder.
-
公开(公告)号：US20220017600A1
公开(公告)日：2022-01-20
申请号：US17184692
申请日：2021-02-25
发明人： Asya Grinberg , John Knopf , Robert S. Pearsall , Ravindra Kumar , Jasbir Seehra , Kristian Pietras
IPC分类号： C07K14/71
摘要： In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
-
-
-
-
-
-
-
-
-
搜索结果
324 条记录 (耗时 0.069 秒)
